Search results
Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it.
BioPharma Dive via Yahoo Finance· 5 days agoWeiss’ new startup, Marea Therapeutics, officially joined the hunt Tuesday, launching with $190...
Biotech startup raises $190 million to focus on new approach to heart attack, stroke and more - San...
The Business Journals· 5 days agoA serial biotech entrepreneur, a longtime UCSF researcher, a shelved Big Pharma drug and $190...
Izokibep Enthesitis Benefit Lacking in Phase 2b/3 PsA Trial
Medscape· 4 days agoThe primary efficacy endpoint was met, but the novel small molecule therapeutic did not reduce...
Cellect Your Weapon: Navigating Potential Arguments in the Aftermath of In re Cellect
The National Law Review· 2 days agoThe Patent Trial & Appeal Board found several related Cellect patents invalid for ODP in view of...
Lilly and subsidiary Point Biopharma accused of patent infringement of cancer drugs - Indianapolis...
Indianapolis Business Journal· 6 days agoThe research foundation filed a complaint in U.S. District Court on Thursday. Companies Endocyte...
Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe company’s money woes started last year when it stopped development work on its gene therapy...
Gateway - Quartz
Quartz· 5 days agoModerna stock rose after new data suggested that its experimental vaccine could be used to treat a variety of cancers. The American Society of Health-System Pharmacists said the number of ongoing ...
New JAK 1 Inhibitor Proves Promising in Phase 3 RA Trial
Medscape· 4 days agoThe highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients...
Osteoarthritis Drugs Need Trials With Appropriate Endpoints
Medscape· 2 days agoThe hypothesis that pivotal clinical trials for osteoarthritis (OA)-modifying therapies are not...
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Zacks via Yahoo Finance· 2 days agoFurther, BCYC collaborates with biopharmaceutical companies and organizations to develop programs in...